Cg Oncology, Inc. · NASDAQ:CGON
Cg Oncology — EAU 2025
7 slides from Cg Oncology's conference presentation, November 2025
Slide 1: Trial in Progress: PIVOT-006 Phase 3 Adjuvant Cretostimogene vs Surveillance in IR-NMIBC
Trial in Progress: PIVOT-006- A Phase 3, Randomized Study of Adjuvant Intravesical Cretostimogene Grenadenorepvec versus Surveillance for the Treatment of Intermediate-Risk Non-Muscle Invasive Bladder Cancer Siamak Daneshmand, MD
Slide 2: Conflict of Interest Disclosure
Conflict of Interest Disclosure • Consultant- CG Oncology
Slide 3: What is Cretostimogene Grenadenorepvec?
What is Cretostimogene Grenadenorepvec? • Conditionally replicating, highly immunogenic adenovirus • Under regulation of the human E2F-1 promoter • Selective for RB-E2F pathway alterations • Encodes GM-CSF transgene • Oncolytic immunotherapy with dual MOA • Viral replication results in tumor lysis •
Slide 4: Intermediate-Risk NMIBC Study Considerations
Intermediate-Risk NMIBC Study Considerations • Considerable risk of recurrence1,2 • No standard of care treatment is approved by the US FDA for IR-NMIBC • Surveillance as the control arm is appropriate: • Best comparator to determine benefit of adjuvant treatment • Low risk of progression1,2 • Consi
Slide 5: Phase 3 Adjuvant Cretostimogene Versus Surveillance for IR NMIBC
Phase 3 Adjuvant Cretostimogene Versus Surveillance for IR NMIBC Intermediate-Risk NMIBC Cretostimogene vs Surveillance Primary Endpoint: Randomized (1:1), Two Arms, Open-Label (n=364) Recurrence-Free Survival Population / Key Entry Criteria Study Design / Regimen Additional Endpoints • AUA definiti
Slide 6: SUO-CTC Trial in Progress: PIVOT-006
SUO-CTC Trial in Progress: PIVOT-006 • Over 90 North American sites participating • First enrollments January 2024 • Expected enrollment period – 30 Months • Rapid enrollment; one-third recruited • At least 1 year of follow-up • NCT06111235
Slide 7: Thank you for your attention!
Thank you for your attention!